The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 801–900 of 1,006
Advanced proteomics approaches to unravel protein homeostasis
Grandi, P., & Bantscheff, M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.02.001 · Cited by 20
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
Li, S., Vallet, S., Sacco, A., Roccaro, A. M., Lentzsch, S., & Podar, K. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1605354 · Cited by 19
Novel insights into the mechanism of action of lenalidomide
Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 20
Exploiting large-scale drug-protein interaction information for computational drug repurposing
Liu, R., Singh, N. P., Tawa, G. J., Wallqvist, A., & Reifman, J. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-210 · Cited by 18
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 19
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
Walker, Z. J., Idler, B. M., Davis, L. N., Stevens, B. M., VanWyngarden, M. J., Ohlstrom, D. J., Bearrows, S. C., Hammes, A., Smith, C. A., Jordan, C. T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2246 · Cited by 19
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
Shimizu, N., Asatsuma‐Okumura, T., Yamamoto, J., Yamaguchi, Y., Handa, H., & Ito, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02801-y · Cited by 19
Davis, L. N., Walker, Z. J., Reiman, L. T., Parzych, S. E., Stevens, B. M., Jordan, C. T., Forsberg, P. A., & Sherbenou, D. W. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0256 · Cited by 19
Song, Y., Zhang, Y., Wang, Z., Lin, Y., Cao, X., Han, X., Li, G., Hou, A., & Han, S. (2024) · Oncogene · doi:10.1038/s41388-024-03118-w · Cited by 19
Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway
Mitsiades, C. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5748 · Cited by 19
Self-citationLenalidomide overcomes the immunosuppression of regulatory CD8+CD28− T-cells
Neuber, B., Dai, J., Waraich, W. A., Awwad, M. H. S., Engelhardt, M., Schmitt, M. W., Medenhoff, S., Witzens‐Harig, M., Ho, A. D., Goldschmidt, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21516 · Cited by 18
Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3
Liu, X., Li, H., Zhang, Q., Zeng, X., & Liu, S.-Q. (2018) · Medical Science Monitor · doi:10.12659/msm.907058 · Cited by 18
Sawamura, N., Yamada, M., Fujiwara, M., Yamada, H., Hayashi, H., Takagi, N., & Asahi, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-20911-2 · Cited by 18
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Petrucci, M. T., Ricciardi, M. R., Molfetta, R., Paolini, R., Santoni, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1562-9 · Cited by 19
Won, H.-R., Lee, D. H., Yeon, S.-K., Ryu, H., Kim, G. W., & Kwon, S. H. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4828 · Cited by 19
Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro
He, X., Dou, A., Feng, S., Roman-Rivera, A., Hawkins, C., Lawley, L., Zhang, J., Wunderlich, M., Mizukawa, B. E., Halene, S., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.05.001 · Cited by 18
Murugesan, A., Lassalle-Claux, G., Hogan, L., Vaillancourt, E., Selka, A., Luiker, K., Kim, M. J., Touaibia, M., & Reiman, T. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00350 · Cited by 20
Metabolic Gatekeepers of Pathological B Cell Activation
Sadras, T., Chan, L. N., Xiao, G., & Müschen, M. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-061020-050135 · Cited by 18
GFI1 Cooperates with IKZF1/IKAROS to Activate Gene Expression in T-cell Acute Lymphoblastic Leukemia
Sun, W., Guo, J., McClellan, D., Poeschla, A., Bareyan, D., Casey, M. J., Cairns, B. R., Tantin, D. R., & Engel, M. E. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0352 · Cited by 18
Lagreca, I., Riva, G., Nasillo, V., Barozzi, P., Castelli, I., Basso, S., Bettelli, F., Giusti, D., Cuoghi, A., Bresciani, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095242 · Cited by 20
Moyer, A. J., Fernandez, F., Li, Y., Klinedinst, D. K., Florea, L., Kazuki, Y., Oshimura, M., & Reeves, R. H. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049712 · Cited by 26
Mitochondrial cereblon functions as a Lon-type protease
Kataoka, K., Nakamura, C., Asahi, T., & Sawamura, N. (2016) · Scientific Reports · doi:10.1038/srep29986 · Cited by 19
Millrine, D., Tei, M., Gemechu, Y., & Kishimoto, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611751113 · Cited by 19
Misiewicz-Krzemińska, I., Corchete, L. A., Rojas, E. A., Martínez‐López, J., García‐Sánz, R., Oriol, A., Bladé, J., Lahuerta, J. J., Miguel, J. F. S., Mateos, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181628 · Cited by 19
Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide
Yamamoto, K., Kitawaki, T., Sugimoto, N., Fujita, H., Kawase, Y., Takaori‐Kondo, A., & Kadowaki, N. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.05.012 · Cited by 19
Imaging dynamic cell signaling in vivo with new classes of fluorescent reporters
Shu, X. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.09.004 · Cited by 18
In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation
Zheng, Y., Singh, A., Niu, Z., Marin, V. L., Young, J., Richardson, P. L., Hemshorn, M. L., Cooley, R. B., Karplus, P. A., Puvar, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c02741 · Cited by 17
Sculpting the proteome with small molecules
King, R. W., & Finley, D. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1671 · Cited by 17
Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery
Ding, Y., Xing, D., Fei, Y., Luo, S., & Lu, B. (2024) · Medicine Plus · doi:10.1016/j.medp.2023.100004 · Cited by 19
DCAF15 control of cohesin dynamics sustains acute myeloid leukemia
Grothusen, G. P., Chang, R., Cao, Z., Zhou, N., Mittal, M., Datta, A., Wulfridge, P., Beer, T., Wang, B., Zheng, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49882-x · Cited by 17
Zaman, S. U., Pagare, P. P., Ma, H., Hoyle, R. G., Zhang, Y., & Li, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00122b · Cited by 17
Yamashita, M., Ogawa, C., Zhang, B., Kobayashi, T., Nomura, A., Barker, C. S., Zou, C., Yamanaka, S., Hayashi, K., Shinkai, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54308-9 · Cited by 18
Primed for degradation: How weak protein interactions enable molecular glue degraders
Hanzl, A., Inghelram, C., Schmitt, S., & Thomä, N. H. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103052 · Cited by 17
Trends in small-molecule probes for lipid droplets
Tu, Y., Zhang, W., Yan, J., Wang, M., Xu, B., & Xie, Y. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118287 · Cited by 17
Khan, A., Muzaffar, J., Murthy, H. S., Wingard, J. R., & Moreb, J. S. (2018) · Case Reports in Hematology · doi:10.1155/2018/9052314 · Cited by 17
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
Yang, L., Chen, J., Han, X., Zhang, E., Huang, X., Guo, X., Chen, Q., Wu, W., Zheng, G., He, D., et al. (2018) · Protein & Cell · doi:10.1007/s13238-017-0500-9 · Cited by 18
Tang, C., Zhang, Q., Wu, S., Tang, M., Liang, Q., Lin, X., Gao, Y., & Ge, Z. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03465-3 · Cited by 17
Design and synthesis of new lenalidomide analogs via Suzuki cross‐coupling reaction
Xiao, D., Wang, Y., Wang, H., Zhou, Y., Li, J. X., Lu, W. P., & Jin, J. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.201900376 · Cited by 17
Multispecific drugs: the fourth wave of biopharmaceutical innovation
Wang, Y., & Yang, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0201-3 · Cited by 17
Sato, T., Ito, T., & Handa, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629326 · Cited by 18
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 19
Zhou, L., & Xu, G. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167457 · Cited by 17
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 18
Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios
Verano, A. L., You, I., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Fischer, E. S., Wang, E. S., & Gray, N. S. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00439 · Cited by 17
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Alhuraiji, A., Naqvi, K. Z., Huh, Y. O., Ho, C., Verstovšek, S., & Bose, P. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1264 · Cited by 17
Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma
Rauch, D. A., Olson, S. L., Harding, J. C., Sundaramoorthi, H., Kim, Y., Zhou, T., MacLeod, A. R., Challen, G. A., & Ratner, L. (2020) · Retrovirology · doi:10.1186/s12977-020-00535-z · Cited by 17
Ren, Y., Wang, M., Couto, S. S., Hansel, D. E., Miller, K., Lopez‐Girona, A., Bjorklund, C. C., Gandhi, A. K., Thakurta, A., Chopra, R., et al. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000246 · Cited by 18
Wada, T., Asahi, T., & Sawamura, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.091 · Cited by 18
Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation
Spiteri, V. A., Segal, D., Correa-Sáez, A., Iso, K., Casement, R., Ordoño, M. M. I., Nakasone, M. A., Sathe, G. J., Schätz, C., Peters, H. E., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02224-y · Cited by 19
Gu, W., Liu, X., Shen, Y., Gong, Y.-T., Chen, Y., Lin, J., Lu, D., Zhang, L.-J., Chen, H., Jin, Y., et al. (2024) · Theranostics · doi:10.7150/thno.97662 · Cited by 17
Zandi, T. A., Romanowski, M. J., Viscomi, J., Gunderson, K., Tan, Z. Y., Tong, B., Bonazzi, S., Zécri, F. J., Schreiber, S. L., & Michaud, G. A. (2026) · Nature Communications · doi:10.1038/s41467-026-71512-x · Cited by 17
Ganesan, S., Palani, H. K., Balasundaram, N., David, S., Devasia, A. J., George, B., & Mathews, V. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0431 · Cited by 17
Park, S., Jo, S.-H., Kim, J.-H., Kim, S., Ha, J. D., Hwang, J. Y., Lee, M. Y., Kang, J. S., Han, T.-S., Park, S. G., et al. (2020) · Cancers · doi:10.3390/cancers12092541 · Cited by 17
Harnessing the Immune System to Fight Multiple Myeloma
Krejcik, J., Barnkob, M. B., Nyvold, C. G., Larsen, T. S., Barington, T., & Abildgaard, N. (2021) · Cancers · doi:10.3390/cancers13184546 · Cited by 17
Discovery of potential novel CRBN modulators by virtual screening and bioassay
Xiong, F., Kong, L., Chen, L., Xue, M., Cao, F., Zhang, S., Li, H., Yan, H., Li, Y., & Zuo, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114355 · Cited by 16
Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors
Driscoll, J. J., & Brailey, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9698-5 · Cited by 16
CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation
Kowalski, T. W., Gomes, J. D. A., Caldas-Garcia, G. B., Fraga, L. R., Paixão‐Côrtes, V. R., Recamonde‐Mendoza, M., Sanseverino, M. T. V., Schüler‐Faccini, L., & Vianna, F. S. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-57512-x · Cited by 19
A small molecule VHL molecular glue degrader for cysteine dioxygenase 1Preprint
Tutter, A. V., Buckley, D. L., Golosov, A. A., Ma, X., Shu, W., McKay, D. J., Darsigny, V., Dovala, D., Beckwith, R. E. J., Solomon, J. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.25.576086 · Cited by 18
Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system
Xiao, X., Nie, Y., & Leng, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1653452 · Cited by 18
Li, J., Slaga, D., Johnston, J., & Junttila, T. T. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0498 · Cited by 16
Functional implications and therapeutic targeting of androgen response elements in prostate cancer
Senapati, D., Sharma, V., Rath, S. K., Rai, U., & Panigrahi, N. (2023) · Biochimie · doi:10.1016/j.biochi.2023.07.012 · Cited by 18
Liu, Y., Mo, C. C., Hartley-Brown, M. A., Sperling, A. S., Midha, S., Yee, A. J., Bianchi, G., Piper, C., Tattersall, A., Nadeem, O., et al. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2382897 · Cited by 16
Yu, Y., Yao, Q., Song, D., Tang, K., Tang, Z., Hu, M., Luo, Y., & Xie, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117893 · Cited by 15
Another action of a thalidomide derivative
Ito, T., & Handa, H. (2015) · Nature · doi:10.1038/nature14628 · Cited by 16
Wang, A. C., Pham, H. T., Lipps, J., Brittain, S. M., Harrington, E. M., Wang, Y., King, F., Russ, C., Pan, X., Hoepfner, D., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00656 · Cited by 17
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond
Lue, J. K., O’Connor, O. A., & Bertoni, F. (2020) · Annals of Lymphoma · doi:10.21037/aol-20-20 · Cited by 15
Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation
Fionda, C., Stabile, H., Molfetta, R., Kosta, A., Peruzzi, G., Ruggeri, S., Zingoni, A., Capuano, C., Soriani, A., Paolini, R., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149269 · Cited by 15
Park, I., Phan, T. M., & Fang, J. (2021) · Cancers · doi:10.3390/cancers13205084 · Cited by 15
Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
Moscvin, M., Ho, M., & Bianchi, G. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.93 · Cited by 17
Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents
Ne, E., Crespo, R., Izquierdo-Lara, R. W., Rao, S., Koçer, S., Górska, A., van Staveren, T., Kan, T. W., van de Vijver, D. A. M. C., Dekkers, D. H. W., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac407 · Cited by 15
Семочкин, С. В. (2022) · Гематология и трансфузиология · doi:10.35754/0234-5730-2022-67-2-240-260 · Cited by 17
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
Chen, L., & Gooding, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038329 · Cited by 16
Advances in the potential roles of Cullin-RING ligases in regulating autoimmune diseases
Zhang, X., Liu, Y., Zhang, T., Tan, Y., Dai, X., Yang, Y., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125224 · Cited by 18
Cul-4 inhibition rescues spastin levels and reduces defects in hereditary spastic paraplegia models
Sardina, F., Carsetti, C., Giorgini, L., Fattorini, G., Cestra, G., & Rinaldo, C. (2024) · Brain · doi:10.1093/brain/awae095 · Cited by 16
The emerging role of targeted protein degradation to treat and study cancer
Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 16
Exploring Ubiquitin-specific proteases as therapeutic targets in Glioblastoma
Samuel, V. P., Moglad, E. H. O., Afzal, M., Kazmi, I. A., Alzarea, S. I., Ali, H., Almujri, S. S., Abida, A., Imran, M., Gupta, G., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155443 · Cited by 15
Bolomsky, A., Hübl, W., Spada, S., Müldür, E., Schlangen, K., Heintel, D., Rocci, A., Weißmann, A., Fritz, V., Willheim, M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24634 · Cited by 15
Choi, T.-Y., Lee, S., Kim, S., Jo, Y., Park, C., & Choi, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-36367-3 · Cited by 17
Primary central nervous system lymphoma: Novel precision therapies
Mondello, P., Mian, M., & Bertoni, F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.009 · Cited by 16
Alberge, J.-B., Magrangeas, F., Wagner, M., Denié, S., Guérin‐Charbonnel, C., Campion, L., Attal, M., Avet‐Loiseau, H., Carell, T., Moreau, P., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00953-y · Cited by 15
Identification of an allosteric site on the E3 ligase adapter cereblon
Dippon, V. N., Rizvi, Z., Choudhry, A. E., Chung, C.-W., Alkuraya, I. F., Xu, W., Tao, X. B., Jurewicz, A. J., Schneck, J. L., Chen, W., et al. (2026) · Nature · doi:10.1038/s41586-025-09994-w · Cited by 14
Sridhar, R., Hoff, O., & Muellner, M. K. (2022) · Molecules · doi:10.3390/molecules27238119 · Cited by 14
Degron tagging for rapid protein degradation in mice
Hernández-Morán, B. A., Taylor, G. C. A., Lorente‐Macías, Á., & Wood, A. J. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050613 · Cited by 15
Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN
Wang, J., Heinz, M., Han, K., Shah, V. J., Hasselbeck, S., Schwalm, M. P., Rathore, R., Hummer, G., Zhou, J., Đikić, I., et al. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.101960 · Cited by 14
A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression
Xue, Z., Qin, L., Xuan, H., Luo, K., Huang, M., Xie, L., Su, Y., Xu, L., Harsh, J., Dale, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado1432 · Cited by 17
Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond
Teoh, P. J., Koh, M. Y., Mitsiades, C. S., Gooding, S., & Chng, W. J. (2024) · Haematologica · doi:10.3324/haematol.2024.285636 · Cited by 18
Self-citationEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
Larsen, J. T., & Kumar, S. K. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0009-4 · Cited by 14
Zou, J., Jones, R. J., Wang, H., Kuiatse, I., Shirazi, F., Manasanch, E. E., Lee, H. C., Sullivan, R., Fung, L. M., Richard, N., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01943-6 · Cited by 14
Cereblon: promise and challenges for combating human diseases
Kim, H. K., Seol, J. E., Ahn, S. W., Jeon, S., Park, C., & Han, J. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02624-0 · Cited by 15
Liu, L., Shi, L., Wang, Z., Zeng, J., Wang, Y., Xiao, H., & Zhu, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839857 · Cited by 18
Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie · doi:10.1002/ange.201901336 · Cited by 14
IKZF3 modulates cerebral ischemia/reperfusion injury by inhibiting neuroinflammation
Meng, C., Chen, S., He, Q., Tan, J., Wu, J., & Zhao, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109480 · Cited by 14
Degradation of extracellular and membrane proteins in targeted therapy: Status quo and quo vadis
Li, Z., Ma, S., Zhang, S., Ma, Z., Du, L., & Li, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103716 · Cited by 15
Enzyme Inhibition and Inactivation
Silverman, R. B., Xue, F., & Juncosa, J. I. (2004) · Elsevier eBooks · doi:10.1016/b978-0-08-051337-9.50010-9 · Cited by 14
Chemical Methods to Knock Down the Amyloid Proteins
Gao, N., Chen, Y., Zhao, Y., & Li, Y. (2017) · Molecules · doi:10.3390/molecules22060916 · Cited by 14
Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin
Verheul, T. C. J., Trinh, V. T., Vázquez, O., & Philipsen, S. (2020) · ChemMedChem · doi:10.1002/cmdc.202000574 · Cited by 15
Dong, X., Han, Y., Zhang, E., Wang, Y., Zhang, P., Wang, C., Zhong, L., & Li, Q. (2021) · Aging · doi:10.18632/aging.202823 · Cited by 14
When and How to Treat Relapsed Multiple Myeloma
Nathwani, N., Bertamini, L., Banerjee, R. K., Gay, F., Shah, N. D., & Krishnan, A. Y. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320129 · Cited by 14
Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm
Giannikopoulos, P., & Parham, D. M. (2021) · Pediatric and Developmental Pathology · doi:10.1177/10935266211013621 · Cited by 14
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.